articleThe LancetJan 25, 2025Closed access

Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial

Sorbonne Université · Hôpital Saint-Antoine · +28 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

165
total citations
FWCI
129.57
Percentile
100%
References
23
Citations per year

Authors

29

Topics & keywords

Keywords
  • Nivolumab
  • Ipilimumab
  • Medicine
  • Open label
  • Colorectal cancer
  • Microsatellite instability
  • Oncology
  • Internal medicine
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding